UnitedHealth price target raised to $325 from $290 at BofA

BofA analyst Kevin Fischbeck raised the firm’s price target on UnitedHealth (UNH) to $325 from $290 and keeps a Neutral rating on the shares. Berkshire Hathaway (BRK.B) (BRK.A) investing is “a positive sign,” but it really only reaffirms the widely held view of many investors that the company’s – and most managed care organizations’ – earnings are depressed. The firm is generally favorable on UnitedHealth and sees the potential for upside in 2027, but it adds that the potentially most important datapoint for UnitedHealth and Medicare Advantage focused names broadly will be the 2027 MA rate update that will be released in February 2026. The company’s “solid, yet modest growth” guidance pointing to $16.80-$17 of EPS in 2026, “seems like a reasonable rebasing,” but the firm doesn’t expect dramatic upside to that range next year as UnitedHealth is best served by keeping the bar low, the analyst added.